BioCardia (NASDAQ:BCDA – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.
Institutional & Insider Ownership
20.6% of BioCardia shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 20.0% of BioCardia shares are owned by company insiders. Comparatively, 6.3% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares BioCardia and Protalix BioTherapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $71,000.00 | 131.71 | -$11.57 million | ($4.19) | -0.49 |
| Protalix BioTherapeutics | $65.49 million | 1.95 | $8.31 million | ($0.13) | -13.35 |
Analyst Ratings
This is a breakdown of recent ratings and price targets for BioCardia and Protalix BioTherapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 0 | 0 | 1 | 0 | 3.00 |
| Protalix BioTherapeutics | 0 | 0 | 0 | 0 | 0.00 |
BioCardia presently has a consensus target price of $25.00, indicating a potential upside of 1,125.49%. Given BioCardia’s stronger consensus rating and higher possible upside, research analysts plainly believe BioCardia is more favorable than Protalix BioTherapeutics.
Profitability
This table compares BioCardia and Protalix BioTherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | -1,999.77% | N/A | -208.38% |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
Risk & Volatility
BioCardia has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
Summary
BioCardia beats Protalix BioTherapeutics on 9 of the 14 factors compared between the two stocks.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
